Elevance Health (ELV) Delivers Q2 2026 Earnings Beat and Raises Full-Year Guidance
Key Takeaways
- Reported Q2 2026 operating revenue of $49.8 billion, up 0.8% year over year.
- Diluted EPS reached $6.71 and adjusted diluted EPS hit $7.45, exceeding internal outlook.
- Company raised full-year 2026 GAAP diluted EPS guidance to at least $20.10 and adjusted diluted EPS to at least $27.00.
- Operating cash flow guidance increased to at least $6.0 billion for the full year.
- Benefit expense ratio rose to 89.7%, while targeted investments in capabilities increased the adjusted operating expense ratio.
- Share repurchases and dividends continued, with $234 million spent on buybacks during the quarter.
Earnings Context and Why It Matters
Elevance Health, a leading diversified healthcare company, delivers critical insights into medical cost trends, membership dynamics, and operational efficiency through its quarterly results. The second quarter often highlights summer utilization patterns and progress on cost-management initiatives. Investors closely monitor these reports for signals on premium yields, government program performance, and Carelon segment growth, which influence the broader health benefits sector and long-term earnings visibility.
Reported Results
Elevance Health reported second quarter 2026 operating revenue of $49.8 billion, an increase of 0.8% from the prior-year quarter. Diluted earnings per share totaled $6.71, while adjusted diluted EPS reached $7.45, supported by favorable benefit expense trends and a net below-the-line benefit of approximately $0.80 per share. The Health Benefits segment generated $42.7 billion in operating revenue, and Carelon contributed $19.2 billion. The company raised its full-year 2026 GAAP diluted EPS guidance to at least $20.10 and adjusted diluted EPS guidance to at least $27.00. Operating cash flow guidance was lifted to at least $6.0 billion. I also checked this using Tickeron’s AI Screener to compare the results against peers.
Market Reaction and Investor Sentiment
Shares initially reacted to the earnings beat and raised guidance but faced pressure amid higher medical cost trends and margin commentary. Investor focus centered on the sustainability of cost initiatives and membership trends in government segments. The results reinforced confidence in operational execution while highlighting ongoing investments aimed at long-term efficiency.
Forward Outlook and Key Factors to Monitor
Management emphasized accelerating investments in medical cost management, member experience, provider connectivity, and Carelon’s integrated solutions. These efforts are expected to support consistent performance and a return to at least 12% adjusted EPS growth in 2027.
Investors should watch medical cost trends in government businesses and progress on Individual ACA performance. Membership attrition in Medicare Advantage and Medicaid remains a key variable.
Operating expense discipline amid targeted investments will influence margin trajectories. Cash flow generation and capital return programs, including share repurchases, provide additional context for balance sheet strength.
Broader industry dynamics around regulatory changes and healthcare utilization will continue to shape the outlook. The company’s diversified portfolio offers visibility into multiple growth areas, including specialty pharmacy and risk-based solutions.
A Closer Look at Research Tools
From what I see, staying on top of earnings details like these benefits from solid analytical support. One resource I turn to regularly is Tickeron’s AI Screener. It is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. I find it useful for putting individual company results into broader context without spending hours on manual comparisons.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsContributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
ELV in downward trend: 10-day moving average broke below 50-day moving average on October 02, 2026
The 10-day moving average for ELV crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ELV as a result. In 53 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.
The Moving Average Convergence Divergence Histogram (MACD) for ELV turned negative on September 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 26 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
ELV broke above its upper Bollinger Band on September 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ELV's RSI Indicator exited the oversold zone, 15 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 38 of 64 cases where ELV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.
ELV moved above its 50-day moving average on October 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELV advanced for three days, in 184 of 323 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The Aroon Indicator entered an Uptrend today. In 131 of 231 cases where ELV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.907) is normal, around the industry mean (3.247). P/E Ratio (17.452) is within average values for comparable stocks, (139.958). ELV's Projected Growth (PEG Ratio) (1.291) is slightly higher than the industry average of (0.786). Dividend Yield (0.017) settles around the average of (0.009) among similar stocks. P/S Ratio (0.453) is also within normal values, averaging (0.569).
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. ELV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 85 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock better than average.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of life, hospital and medical insurance plans
Industry ManagedHealthCare
Advertisement